INCLUSION CRITERIA
To participate in the Menstrual Cycle Pilot Study, a woman must:
Must be at least 25 years of age (or 5 years younger than the age at diagnosis of the youngest family member with a tumor associated with the Breast-Ovarian Cancer Syndrome) and less than 56 years of age.
Must be premenopausal as determined by menstrual history (no change in menstrual pattern in prior 6 months) and an FSH level less than 15 mIU/ml obtained on the third day of the menstrual cycle.
Must be a known mutation carrier or be a first- or second-degree relative of an individual with a tumor associated with the Breast-Ovarian Cancer Syndrome in a family with a known BRCA mutation.
Have undergone genetic counseling and risk assessment.
Agree to release of genetic test result for stratification purposes, whether or not she has chosen to receive individual test results for clinical decision-making.
Have an ECOG performance status of 0-1.
Have a normal fasting blood glucose (for PET studies only).
Be able to provide informed consent.
EXCLUSION CRITERIA
A history of menstrual cycle irregularities over the previous 6 months, including history of cycles less than 26 days or more than 35 days.
Use of the following drugs within 6 months prior to study entry: steroids, selective estrogen receptor modulators (SERMs) or hormonal agents (including tamoxifen, raloxifene, estrogen, DHEA, anabolic steroids, oral contraceptives, depoprovera, progestin IUD, oral progestins, norplant, or drugs to induce ovulation.
Pregnancy or lactation within 12 months of enrollment.
Abnormal CA-125 level.
History of invasive cancer except for non-melanoma skin cancer or cervical carcinoma in situ.
History of diabetes (excluded from PET studies only).
Creatinine greater than 2.
Previous bilateral mastectomy or bilateral radiation therapy.
History of DCIS or LCIS .
Weight over 136 kilograms.
Allergy to gadolinium.
Allergy to lidocaine or Marcaine (bupivacaine) (excluded from breast duct lavage only).
Medical or psychiatric disorder which, in the opinion of the Principal Investigator, would preclude informed consent or ability to participate in clinical research.